Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1636 1653
This examiner grants 25% of resolved cases
Ashley Taylor White is a patent examiner assigned to Art Unit 1636 within Tech Center 1600. The examiner's professional record includes 20 resolved cases. The data indicates an allowance rate of 25.0% for these applications. This figure serves as a primary indicator of the probability of success for cases on this docket. Additionally, the median days to allowance is 1362, which establishes a specific timeframe for the prosecution process. These metrics offer a foundational understanding of the examiner's approach to patent applications.
The interview lift for this examiner is 46.7%. This 46.7% lift shows the change in the likelihood of allowance when an interview is conducted compared to the 25.0% base rate. With 20 resolved cases, the data provides a view of the examiner's historical performance. The 1362-day median pendency is a key metric for managing client expectations regarding the duration of the patent application process in Tech Center 1600. Practitioners should evaluate the allowance rate and the interview lift to determine the most effective strategy for their specific cases.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18037320 | MICROORGANISM HAVING ENHANCED L-GLUTAMINE PRODUCING ABILITY, AND L-GLUTAMINE PRODUCING METHOD USING SAME | Non-Final OA | CJ CHEILJEDANG CORPORATION |
| 17761630 | METHOD FOR SEPARATING DISODIUM 5'-INOSINATE | Final Rejection | CJ CHEILJEDANG CORPORATION |
| 18702280 | CUSTOM BACTERIAL STRAIN FOR RECOMBINANT PROTEIN PRODUCTION | Non-Final OA | ModernaTX, Inc. |
| 17885805 | MASS SPECTROMETRY-BASED STRATEGY FOR DETERMINING PRODUCT-RELATED VARIANTS OF A BIOLOGIC | Final Rejection | Regeneron Pharmaceuticals, Inc. |
| 17863303 | MASS SPECTROMETRY-BASED STRATEGY FOR DETERMINING PRODUCT-RELATED VARIANTS OF A BIOLOGIC | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17595833 | APPLICATION OF BLAUTIA SP B2132 STRAIN IN PREVENTING AND/OR TREATING INFLAMMATORY BOWEL DISEASE | Final Rejection | Zhejiang university |
| 18287424 | SUGAR CHAIN ANALYSIS METHOD | Final Rejection | Shimadzu Corporation |
| 18590736 | GLYCOSIDE HYDOLASES AND THEIR USE IN PREVENTING AND/OR TREATING A PATHOGENIC INFECTION IN AN ANIMAL | Non-Final OA | INTERNATIONAL N&H DENMARK APS |
| 18578609 | NOVEL ENZYMES FOR THE PRODUCTION OF E-COPALOL | Final Rejection | AMYRIS, INC. |
| 17801907 | RECOMBINANT FIBCD1 AND USE THEROF IN THE TREATMENT OF MUSCLE ATROPHY | Non-Final OA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. |
| 18023912 | MICROBIAL PRODUCTION OF ARTEMISINIC ACID AND DERIVATIVES | Non-Final OA | Manus Bio Inc. |
| 18270490 | RECOMBINANT STRAIN WITH MODIFIED GENE BBD29_04920 FOR PRODUCING L-GLUTAMIC ACID, AND METHOD FOR CONSTRUCTING THE SAME AND USE THEREOF | Non-Final OA | INNER MONGOLIA EPPEN BIOTECH CO., LTD. |
| 18006728 | CATALYTICALLY ACTIVE PROTEIN FOAMS, AND METHOD FOR PRODUCING SAME | Final Rejection | Karlsruher Institut fuer Technologie |
| 18017260 | MICROBIAL THERAPY | Non-Final OA | BEO THERAPEUTICS |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy